BRIEF-Macrogenics presents data from phase 1 research study of MGD010

Macrogenics Inc * Macrogenics presents information from phase 1 research of mgd010 at
yearly european congress of rheumatology (eular 2016).

* Mgd010 was well endured at all dosage levels with no.
severe unfavorable results.

* Bispecific particle based on dart platform at the same time.
targets b-cell antigens, CD32B and CD79B.

Source text for Eikon:.
Further business protection:.


Read More

Leave a Reply

Your email address will not be published. Required fields are marked *